AliveDx Suisse S.A. (“AliveDx”), a global innovator in in-vitro diagnostics, and African Biotechnology Society (ABS), a leading Tunisian diagnostics and life sciences company, have signed a distribution agreement enabling ABS to distribute the MosaiQ® and LumiQ® solutions in Tunisia. The agreement is effective immediately.
This partnership reinforces AliveDx’s commitment to expanding access to innovative diagnostic technologies and delivering both clinical and economic value to healthcare professionals. Through this collaboration, AliveDx and ABS aim to introduce high-quality diagnostic solutions that support earlier diagnosis, improved laboratory efficiency, and enhanced patient care across Tunisia.
“We are pleased to announce our partnership with a key player in Tunisia. We are always eager to collaborate with new partners such as ABS to make a strategic impact on improving patients’ lives in emerging geographies such as Tunisia and North Africa, while expanding access to innovative diagnostic solutions worldwide,” said Manuel O. Méndez, Chief Executive Officer of AliveDx.
“We are delighted to welcome ABS to the AliveDx partner network. Their vision, technical expertise, and commitment to advancing healthcare make them an ideal strategic partner for Tunisia. This collaboration is not only about introducing innovative technologies; it is about building a long-term partnership that will help improve diagnostic capabilities, support healthcare professionals, and ultimately enhance patient care across Tunisia and the broader North African region,” said Khaled Hamed, Head of Global Emerging Markets, AliveDx.
“We are very proud and excited to partner with AliveDx and bring the MosaiQ® and LumiQ® solutions to the Tunisian market as part of our mission to expand our diagnostics portfolio. The addition of AliveDx technologies represents a significant milestone in our growth within the clinical diagnostics sector. The comprehensive turnkey offering of MosaiQ® and LumiQ® will enable us to introduce breakthrough solutions to healthcare providers and laboratories, helping deliver a positive and lasting impact on patient care throughout Tunisia,” said Dr. Imen Nahdi, Founder and Chief Executive Officer of ABS.
African Biotechnology Society (ABS) is a Tunisia-based company founded in 2014 by Dr. Imen Nahdi, specializing in the distribution, promotion, technical support, and maintenance of advanced clinical diagnostics, biotechnology, and research support services throughout Tunisia and selected African markets. The company’s mission is set to contribute to improving healthcare outcomes across Africa while establishing itself as a leading partner in diagnostics and research development.
AliveDx Suisse S.A. and African Biotechnology Society – ABS, have signed a distribution agreement, which will enable ABS to distribute the MosaiQ® and LumiQ® solutions in Tunisia.
Media Contact
AliveDx Suisse S.A.
Route de Crassier 13
1262 Eysins, Switzerland
https://www.alivedx.com
African Biotechnology Society (ABS)
Centre de Vie et d’Affaires, El Agba
2087 Tunis, Tunisia
www.africanbs.com.tn
